Design: Pooled analysis of 4 Phase 2/3 RCTs (N=4,895)
Population: Adults with migraine (with/without aura)
Intervention: Single-dose rimegepant 75 mg vs Placebo
Key endpoints: Pain freedom & MBS freedom at 2h (co-primary)
1. Mechanism & onset profile
Rimegepant acts as a selective CGRP receptor antagonist, blocking neuropeptide signaling in trigeminal system. Clinical differentiation begins early.
45 min
First significant separation from placebo
*Onset observed for both Pain Relief and Pain Freedom endpoints.
2. Primary efficacy outcomes (2h)
+8.2%
Pain Freedom
(20.0% vs 11.8%)
+11.0%
MBS Freedom
(40.2% vs 29.2%)
< 0.0001
P-value
(all endpoints)
Clinical significance: All co-primary and secondary endpoints achieved statistical superiority. Pain Relief showed largest absolute gain (+15.2%), while functional restoration improved by +12.4%.
3. Sustained benefit & safety
Durable efficacy with reduced need for rescue medication. Safety profile comparable to placebo with no cardiovascular signals.
Safety Summary:
Overall AEs:
11.1% vs 9.6%
Serious AEs:
0.1% (both groups)
Nausea:
1.4% vs 1.3%
Key takeaway: Rimegepant establishes new benchmark in acute migraine treatment with rapid onset (45 min), robust 2-hour efficacy across all endpoints (NNT ~12 for pain freedom), and sustained relief extending to 48 hours. Safety profile mirrors placebo, positioning rimegepant as both effective and well-tolerated first-line option. The 75 mg dose demonstrates consistent benefit-risk profile across diverse patient populations.